文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

新型即时生物标志物组合检测鉴别急性细菌性与病毒性呼吸道感染以指导抗生素处方的系统评价

Novel point-of-care biomarker combination tests to differentiate acute bacterial from viral respiratory tract infections to guide antibiotic prescribing: a systematic review.
PubMed 文献 · Clin Microbiol Infect · 2021-05-17

该系统评价纳入20项观察性研究(3514例患者),评估即时生物标志物组合检测鉴别急性呼吸道感染细菌或病毒病因的诊断准确性。18项研究存在高偏倚风险;对两种商业检测的荟萃分析显示,ImmunoXpert和FebriDx对细菌和病毒感染均具有较高的敏感度和特异度,但证据局限性阻碍了确定性结论。

要点

  • 生物标志物组合检测在鉴别呼吸道感染病因方面显示潜在临床效用。
  • 多数研究存在高偏倚风险,证据局限性妨碍得出确定性结论。

核心结论

  • 生物标志物组合检测在鉴别呼吸道感染病因方面显示潜在临床效用,但证据局限性阻碍了确定性结论。

研究设计与样本

  • 系统评价,检索MEDLINE、Embase和Web of Science数据库至2021年2月,纳入20项观察性诊断准确性研究,共3514例患者。
  • 使用QUADAS-2工具评估偏倚风险,对报告超过一项研究的检测进行随机效应模型荟萃分析。

主要发现

  • 18项研究被判定为高偏倚风险。
  • 对于细菌病因,敏感度范围为61%至100%,特异度范围为18%至96%。
  • 对于病毒病因,敏感度范围为59%至97%,特异度范围为74%至100%。
  • ImmunoXpert对细菌感染的汇总敏感度为85%(95%CI 75%-91%,k=4),特异度为86%(95%CI 73%-93%,k=4);对病毒感染的汇总敏感度为90%(95%CI 79%-96%,k=3),特异度为92%(95%CI 83%-96%,k=3)。
  • FebriDx对细菌感染的汇总敏感度为84%(95%CI 75%-90%,k=4),特异度为93%(95%CI 90%-95%,k=4);对病毒感染的汇总敏感度为87%(95%CI 72%-95%,k=4),特异度为82%(95%CI 66%-86%,k=4)。

临床怎么用

  • 生物标志物组合检测可作为辅助手段鉴别呼吸道感染病因,但需结合临床判断,不能仅凭检测结果决定抗生素使用。

局限性

  • 高比例研究存在高偏倚风险,限制了证据的可靠性。
  • 未来研究应在初级保健环境中进行,采用实验性设计评估患者结局和成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute respiratory tract infections (RTIs) are the most common reason to seek medical care, with many patients receiving inappropriate antibiotics. Novel testing approaches to identify aetiology at the point-of-care are required to accurately guide antibiotic treatment. OBJECTIVE: To assess the diagnostic accuracy of biomarker combinations to rapidly differentiate between acute bacterial or viral RTI aetiology. DATA SOURCES: MEDLINE, Embase and Web of Science databases were searched to February 2021. STUDY ELIGIBILITY CRITERIA: Diagnostic accuracy studies comparing accuracy of point-of-care and rapid diagnostic tests in primary or secondary care, consisting of biomarker combinations, to identify bacterial or viral aetiology of RTI. METHODS: Risk of bias was assessed using the QUADAS-2 tool. Sensitivity and specificity of tests reported by more than one study were meta-analysed using a random effects model. RESULTS: Twenty observational studies (3514 patients) were identified. Eighteen were judged at high risk of bias. For bacterial aetiologies, sensitivity ranged from 61% to 100% and specificity from 18% to 96%. For viral aetiologies, sensitivity ranged from 59% to 97% and specificity from 74% to 100%. Studies evaluating two commercial tests were meta-analysed. For ImmunoXpert, the summary sensitivity and specificity were 85% (95% CI 75%-91%, k = 4) and 86% (95% CI 73%-93%, k = 4) for bacterial infections, and 90% (95% CI 79%-96%, k = 3) and 92% (95% CI 83%-96%, k = 3) for viral infections, respectively. FebriDx had pooled sensitivity and specificity of 84% (95% CI 75%-90%, k = 4) and 93% (95% CI 90%-95%, k = 4) for bacterial infections, and 87% (95% CI 72%-95%; k = 4) and 82% (95% CI 66%-86%, k = 4) for viral infections, respectively. CONCLUSION: Combinations of biomarkers show potential clinical utility in discriminating the aetiology of RTIs. However, the limitations in the evidence base, due to a high proportion of studies with high risk of bias, preclude firm conclusions. Future research should be in primary care and evaluate patient outcomes and cost-effectiveness with experimental study designs. CLINICAL TRIAL: PROSPERO registration number: CRD42020178973.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Carlton HC, Savović J, Dawson S, et al. Novel point-of-care biomarker combination tests to differentiate acute bacterial from viral respiratory tract infections to guide antibiotic prescribing: a systematic review. Clin Microbiol Infect. 2021. PMID: 34015531. doi:10.1016/j.cmi.2021.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。